EP Wealth Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.76M | Sell |
26,970
-1,321
| -5% | -$185K | 0.02% | 358 |
|
|
2025
Q4 | $3.47M | Buy |
+28,291
| New | +$3.44M | 0.02% | 341 |
|
|
2025
Q2 | $3.24M | Buy |
29,256
+1,672
| +6% | +$178K | 0.02% | 328 |
|
|
2025
Q1 | $3.09M | Sell |
27,584
-1,720
| -6% | -$177K | 0.02% | 291 |
|
|
2024
Q4 | $2.71M | Sell |
29,304
-24,647
| -46% | -$2.22M | 0.02% | 306 |
|
|
2024
Q3 | $4.52M | Buy |
53,951
+6,492
| +14% | +$495K | 0.04% | 231 |
|
|
2024
Q2 | $3.26M | Buy |
47,459
+527
| +1% | +$35.2K | 0.03% | 222 |
|
|
2024
Q1 | $3.44M | Sell |
46,932
-534
| -1% | -$41.1K | 0.04% | 211 |
|
|
2023
Q4 | $3.85M | Buy |
47,466
+356
| +0.8% | +$27.7K | 0.05% | 192 |
|
|
2023
Q3 | $3.53M | Buy |
47,110
+6,560
| +16% | +$505K | 0.05% | 183 |
|
|
2023
Q2 | $2.69M | Sell |
40,550
-19,450
| -32% | -$1.55M | 0.04% | 212 |
|
|
2023
Q1 | $108 | Buy |
60,000
+52,661
| +718% | +$4.36M | ﹤0.01% | 632 |
|
|
2022
Q4 | $630K | Buy |
+7,339
| New | +$581K | 0.01% | 340 |
|
|
2022
Q3 | – | Sell |
-8,124
| Closed | -$502K | – | 442 |
|
|
2022
Q2 | $502K | Buy |
8,124
+2,944
| +57% | +$182K | 0.01% | 369 |
|
|
2022
Q1 | $308K | Sell |
5,180
-408
| -7% | -$26.1K | 0.01% | 487 |
|
|
2021
Q4 | $406K | Buy |
5,588
+979
| +21% | +$67.4K | 0.01% | 399 |
|
|
2021
Q3 | $322K | Sell |
4,609
-340
| -7% | -$23.9K | 0.01% | 418 |
|
|
2021
Q2 | $341K | Sell |
4,949
-171
| -3% | -$11.4K | 0.01% | 416 |
|
|
2021
Q1 | $331K | Buy |
+5,120
| New | +$330K | 0.01% | 388 |
|
|
2020
Q4 | – | Sell |
-4,047
| Closed | -$256K | – | 461 |
|
|
2020
Q3 | $256K | Buy |
4,047
+151
| +4% | +$10.5K | 0.01% | 310 |
|
|
2020
Q2 | $300K | Sell |
3,896
-1,647
| -30% | -$126K | 0.01% | 307 |
|
|
2020
Q1 | $414K | Buy |
5,543
+1,692
| +44% | +$117K | 0.02% | 273 |
|
|
2019
Q4 | $250K | Sell |
3,851
-753
| -16% | -$49K | 0.01% | 361 |
|
|
2019
Q3 | $292K | Buy |
4,604
+394
| +9% | +$25.8K | 0.01% | 285 |
|
|
2019
Q2 | $284K | Sell |
4,210
-1,020
| -20% | -$67.1K | 0.02% | 245 |
|
|
2019
Q1 | $340K | Buy |
5,230
+242
| +5% | +$16.1K | 0.03% | 194 |
|
|
2018
Q4 | $312K | Sell |
4,988
-38
| -0.8% | -$2.66K | 0.02% | 207 |
|
|
2018
Q3 | $388K | Buy |
+5,026
| New | +$380K | 0.03% | 195 |
|
|
2015
Q1 | – | Sell |
-67,327
| Closed | -$6.35M | – | 134 |
|
|
2014
Q4 | $6.35M | Buy |
67,327
+459
| +0.7% | +$47.5K | 1.05% | 38 |
|
|
2014
Q3 | $7.12M | Sell |
66,868
-51,192
| -43% | -$5.01M | 1.15% | 32 |
|
|
2014
Q2 | $9.79M | Buy |
118,060
+4,757
| +4% | +$370K | 2.27% | 20 |
|
|
2014
Q1 | $8.03M | Sell |
113,303
-8,611
| -7% | -$675K | 2.2% | 24 |
|
|
2013
Q4 | $9.16M | Sell |
121,914
-1,510
| -1% | -$105K | 2.37% | 21 |
|
|
2013
Q3 | $7.76M | Sell |
123,424
-10,442
| -8% | -$624K | 2.44% | 21 |
|
|
2013
Q2 | $6.86M | Buy |
+133,866
| New | +$6.98M | 2.48% | 21 |
|
Other funds holding GILD
VCM
VPM
EP Wealth Advisors's GILD Position: Q1 2026 in Review
EP Wealth Advisors reduced its Gilead Sciences (GILD) stake by 4.7% in Q1 2026, selling an estimated $185K and leaving 26,970 shares worth $3.76M. The position accounts for 0.02% of the portfolio, ranked #358.
EP Wealth Advisors first reported a position in GILD in Q2 2013 and has held it in 35 quarters since. The position peaked at $9.79M in Q2 2014. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- EP Wealth Advisors held 26,970 shares of Gilead Sciences worth $3.76M as of Q1 2026.
- EP Wealth Advisors sold 1,321 Gilead Sciences shares in Q1 2026, an estimated $185K.
- Gilead Sciences made up 0.02% of EP Wealth Advisors's portfolio in Q1 2026, its #358 holding.
- EP Wealth Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 35 quarters since.
- EP Wealth Advisors's Gilead Sciences position peaked at $9.79M in Q2 2014.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.